Total Payments
$1,811
2024 Payments
$19.02
Companies
21
Transactions
114
Medicare Patients
1,224
Medicare Billing
$68,789
Payment Breakdown by Category
Food & Beverage$1,736 (95.9%)
Education$74.99 (4.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,736 | 113 | 95.9% |
| Education | $74.99 | 1 | 4.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $454.18 | 34 | $0 (2019) |
| Astellas Pharma US Inc | $295.53 | 14 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $194.85 | 12 | $0 (2019) |
| Amgen Inc. | $179.97 | 11 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $145.12 | 9 | $0 (2024) |
| AbbVie Inc. | $87.28 | 2 | $0 (2020) |
| PFIZER INC. | $74.38 | 6 | $0 (2019) |
| Lilly USA, LLC | $66.79 | 5 | $0 (2019) |
| Takeda Pharmaceuticals America, Inc. | $64.03 | 5 | $0 (2017) |
| Abbott Laboratories | $47.99 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $19.02 | 1 | AstraZeneca Pharmaceuticals LP ($19.02) |
| 2020 | $16.06 | 1 | AbbVie Inc. ($16.06) |
| 2019 | $306.90 | 20 | Novo Nordisk Inc ($114.27) |
| 2018 | $674.09 | 43 | Novo Nordisk Inc ($205.64) |
| 2017 | $795.15 | 49 | Astellas Pharma US Inc ($140.47) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Respiratory | ||||||
| 02/28/2020 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2019 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Virology & Specialty Care | ||||||
| 06/10/2019 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: DIABETES | ||||||
| 05/28/2019 | Novo Nordisk Inc | Tresiba (Drug), Victoza, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $12.96 | General |
| Category: Diabetes | ||||||
| 05/28/2019 | PFIZER INC. | LYRICA (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 05/13/2019 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: Diabetes | ||||||
| 04/30/2019 | Novo Nordisk Inc | Tresiba (Drug), Victoza, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $12.28 | General |
| Category: Diabetes | ||||||
| 04/26/2019 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Diabetes | ||||||
| 04/17/2019 | Novo Nordisk Inc | Tresiba (Drug), Victoza, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $11.02 | General |
| Category: Diabetes | ||||||
| 04/12/2019 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Hypertriglyceridemia | ||||||
| 04/03/2019 | Novo Nordisk Inc | Tresiba (Drug), Victoza, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Diabetes | ||||||
| 03/25/2019 | Amgen Inc. | Prolia (Biological), Repatha | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Bone Health | ||||||
| 03/08/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: UROLOGY | ||||||
| 03/04/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Neuroscience | ||||||
| 02/25/2019 | Amgen Inc. | Prolia (Biological), Repatha | Food and Beverage | In-kind items and services | $28.07 | General |
| Category: Bone Health | ||||||
| 02/20/2019 | Novo Nordisk Inc | Tresiba (Drug), Victoza, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Diabetes | ||||||
| 02/19/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: UROLOGY | ||||||
| 02/07/2019 | Lilly USA, LLC | TRULICITY (Drug), BASAGLAR | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: Diabetes | ||||||
| 02/06/2019 | Novo Nordisk Inc | Tresiba (Drug), Victoza, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Diabetes | ||||||
| 02/05/2019 | Novo Nordisk Inc | Tresiba (Drug), Victoza, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Diabetes | ||||||
| 01/15/2019 | Novo Nordisk Inc | Tresiba (Drug), Victoza, Xultophy 100/3.6 | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: Diabetes | ||||||
| 12/17/2018 | PFIZER INC. | LYRICA (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $11.46 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 12/07/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: DIABETES | ||||||
| 11/27/2018 | Amgen Inc. | Prolia (Biological), Repatha | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 102 | 106 | $18,855 | $5,846 |
| 2022 | 9 | 267 | 381 | $44,490 | $17,082 |
| 2021 | 9 | 350 | 510 | $49,705 | $21,990 |
| 2020 | 13 | 505 | 646 | $63,379 | $23,873 |
Total Patients
1,224
Total Services
1,643
Medicare Billing
$68,789
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $4,500 | $1,678 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 30 | $5,550 | $1,659 | 29.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 20 | 20 | $4,100 | $1,187 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 17 | $3,315 | $1,184 | 35.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 13 | $1,170 | $114.18 | 9.8% |
| 81003 | Automated urinalysis test | Office | 2023 | 11 | 11 | $220.00 | $24.20 | 11.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 59 | 64 | $11,840 | $4,131 | 34.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 45 | 45 | $9,225 | $3,747 | 40.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 35 | 41 | $7,995 | $3,362 | 42.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $6,900 | $2,556 | 37.0% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 39 | 40 | $3,000 | $1,667 | 55.6% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2022 | 15 | 16 | $1,200 | $819.93 | 68.3% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 16 | 34 | $1,870 | $553.44 | 29.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 18 | 22 | $1,980 | $179.63 | 9.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 17 | 96 | $480.00 | $65.26 | 13.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 64 | 64 | $12,460 | $6,056 | 48.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 80 | 86 | $14,335 | $5,965 | 41.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 38 | $7,410 | $3,442 | 46.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $6,000 | $2,532 | 42.2% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2021 | 46 | 48 | $3,600 | $2,463 | 68.4% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 21 | 21 | $1,575 | $949.83 | 60.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 32 | 35 | $3,005 | $356.03 | 11.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2021 | 31 | 176 | $880.00 | $175.61 | 20.0% |
| 81003 | Automated urinalysis test | Office | 2021 | 21 | 22 | $440.00 | $49.50 | 11.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 65 | 65 | $12,554 | $5,652 | 45.0% |
About Dr. Christopher Hunter, M.D
Dr. Christopher Hunter, M.D is a Emergency Medical Services healthcare provider based in Afton, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1154311959.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Hunter, M.D has received a total of $1,811 in payments from pharmaceutical and medical device companies, with $19.02 received in 2024. These payments were reported across 114 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($1,736).
As a Medicare-enrolled provider, Hunter has provided services to 1,224 Medicare beneficiaries, totaling 1,643 services with total Medicare billing of $68,789. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medical Services
- Other Specialties Family Medicine
- Location Afton, OK
- Active Since 10/24/2005
- Last Updated 01/29/2024
- Taxonomy Code 207PE0004X
- Entity Type Individual
- NPI Number 1154311959
Products in Payments
- Victoza (Drug) $248.21
- TOUJEO (Drug) $145.06
- Myrbetriq (Drug) $140.47
- Tresiba (Drug) $132.37
- Prolia (Biological) $121.36
- Trintellix (Drug) $80.79
- MYRBETRIQ (Drug) $80.07
- JARDIANCE (Drug) $73.22
- FARXIGA (Drug) $72.96
- Androgel (Drug) $71.22
- SOLIQUA (Drug) $49.79
- Repatha (Biological) $43.65
- SYMBICORT (Drug) $40.10
- LYRICA (Drug) $38.25
- DRG IPGs (Device) $36.62
- Trulance (Drug) $33.25
- Xultophy 100/3.6 (Drug) $31.64
- PREVNAR - 13 (Biological) $22.73
- Vascepa (Drug) $22.02
- AIRSUPRA (Drug) $19.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.